All In Biotech

Drug Trial Radar · NCT05599516

Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) Phase III Clinical Trial

A Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial to Evaluate Efficacy, Safety and Immunogenicity of LIBP Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) and BIBP Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) in Healthy Population Aged 18 and Above

Last checked: Nov 19, 2026Latest source record: Nov 10, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 16,000 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

16,000

Planned (sponsor's estimate)

Start

Nov 4, 2022

Primary completion

Oct 2023

Study completion Dec 2023

Sponsor

Sponsor type
Industry
Collaborators
China National Biotec Group Company Limited; Lanzhou Institute of Biological Products Co., Ltd; Beijing Institute of Biological Products Co Ltd.
First posted
Oct 31, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This clinical trial adopts a randomized, double-blind and placebo-controlled design. A total of 16000 participants are planned to be enrolled, of which, Cohort 1: 15000 participants vaccinated with ≥2 doses of inactivated COVID-19 vaccine for ≥6 months will be randomly administered at ratio of 1:1:1 with 1 dose of LIBP-Rec-Vaccine, BIBP-Rec-Vaccine or placebo intramuscularly to the deltoid muscle of upper arm. Cohort 2: 1000 participants vaccinated with ≥2 doses of mRNA COVID-19 vaccine for ≥6 months will be randomly administered at ratio of 1:1 with 1 dose of LIBP-Rec-Vaccine or BIBP-Rec-Vaccine intramuscularly to the deltoid muscle of upper arm.

Conditions

  • COVID-19
  • Coronavirus Infections

Interventions

  • LIBP-Rec-VaccineBiological

    Intramuscular injection of LIBP-Rec-Vaccine in the deltoid muscle of the upper arm

  • BIBP-Rec-VaccineBiological

    Intramuscular injection of BIBP-Rec-Vaccine in the deltoid muscle of the upper arm

  • placeboBiological

    Intramuscular injection of placebo in the deltoid muscle of the upper arm

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohort 1: Efficacy of LIBP-Rec-Vaccine/ BIBP-Rec-Vaccine against COVID-19 of immunization in healthy population aged 18 and above.Time frame: 14th day after vaccination

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sheikh Khalifa Medical City

    SEHA, Abu Dhab, United Arab Emirates · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.